Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable type of RNA—to treat inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The researchers encapsulated selected LNA molecules, which silence a key gene in colitis, within lipid (fat) nanoparticles that serve as targeted drug carriers and injected the nanoparticles into colitis-model mice.